Eli Lilly Announces Results From SURMOUNT-OSA Phase 3 Trials Evaluating Tirzepatide For Moderate-To-Severe Obstructive Sleep Apnea In Adults With Obesity; Achieves All Primary And Key Secondary Endpoints, Including Up To 62.8% Reduction In Apnea-Hypopnea Index
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announced positive results from its SURMOUNT-OSA Phase 3 trials evaluating tirzepatide for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The drug achieved all primary and key secondary endpoints, including up to a 62.8% reduction in the apnea-hypopnea index. Lilly has submitted tirzepatide for FDA approval and will initiate submissions to other global regulatory agencies.

June 21, 2024 | 7:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's tirzepatide achieved significant success in Phase 3 trials for treating moderate-to-severe obstructive sleep apnea in adults with obesity. The drug met all primary and key secondary endpoints, including a 62.8% reduction in the apnea-hypopnea index. Lilly has submitted the drug for FDA approval and plans to submit to other global regulatory agencies soon.
The successful Phase 3 trial results and subsequent FDA submission are likely to positively impact Eli Lilly's stock price in the short term. Achieving all primary and key secondary endpoints, including a significant reduction in OSA severity, demonstrates the drug's efficacy and potential market impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100